Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

September 26, 2024 by Alan Khadavi

Dupixent for COPD (chronic obstructive pulmonary disease)

Dupixent for COPD will be a new indication for this drug after positive phase 3 clinical trials. Dupixent (dupilumab) is a human monoclonal antibody that blocks IL-4 and IL-13 signaling and type 2 inflammation.

The trial which was published in The New England Journal of Medicine. Dupixent decreased the rate of moderate to severe exacerbations over 52 weeks of treatment compared to placebo.

Chronic obstructive pulmonary disease (COPD) is a progressive, inflammatory lung disease characterized by airflow limitation. It is primarily caused by smoking, environmental factors, and genetic predispositions. Despite the availability of therapies such as bronchodilators, corticosteroids, and phosphodiesterase-4 inhibitors, many patients with COPD experience insufficient disease control, particularly in those with high levels of type 2 inflammation. Dupilumab, is currently approved for several type 2 inflammation-mediated diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Recent clinical investigations suggest that dupilumab may also be effective in treating a specific subgroup of COPD patients with elevated eosinophilic inflammation. This article reviews the pathophysiological mechanisms of type 2 inflammation in COPD and the emerging role of dupilumab as a potential therapeutic option.

Introduction

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, with approximately 3.2 million deaths attributed to the disease annually. Characterized by persistent respiratory symptoms and airflow limitation, COPD encompasses chronic bronchitis, emphysema, or a combination of both. Current therapies for COPD include bronchodilators, corticosteroids, and phosphodiesterase-4 (PDE4) inhibitors, which aim to reduce symptoms and slow disease progression. However, many patients with COPD, particularly those with eosinophilic inflammation, exhibit inadequate responses to these therapies, highlighting an unmet need for novel therapeutic options.

Type 2 inflammation, driven by T-helper type 2 (Th2) cells and the production of cytokines such as interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13), plays a role in the pathophysiology of asthma and certain COPD subtypes. This inflammation is characterized by eosinophilic infiltration, which has been associated with disease exacerbations and poor outcomes in COPD. Dupilumab, a monoclonal antibody that inhibits IL-4 and IL-13 signaling through the IL-4Rα subunit, has shown promise in treating eosinophilic asthma, suggesting potential benefits in COPD patients with a similar inflammatory profile.

Pathophysiology of COPD and Type 2 Inflammation

COPD is traditionally viewed as a disease of neutrophilic inflammation; however, recent evidence highlights the heterogeneity of the disease, with some patients exhibiting eosinophilic inflammation. Elevated blood eosinophil levels have been linked to increased exacerbation risk and responsiveness to inhaled corticosteroids (ICS). The identification of this eosinophilic subtype of COPD has spurred interest in therapies targeting type 2 inflammation.

Type 2 inflammation is driven by the dysregulation of cytokines such as IL-4, IL-5, and IL-13, which promote eosinophil recruitment and activation. In COPD, eosinophilic inflammation contributes to airway hyperreactivity, mucus production, and tissue remodeling, all of which exacerbate disease progression and symptom burden. These features parallel those seen in eosinophilic asthma, suggesting that therapies successful in asthma may also benefit a subset of COPD patients with type 2 inflammation.

Mechanism of Action of Dupilumab

Dupilumab is a fully human monoclonal antibody that blocks the IL-4Rα subunit, inhibiting the signaling pathways of both IL-4 and IL-13, two key cytokines in the type 2 inflammatory response. By targeting this shared receptor, dupilumab suppresses Th2-driven inflammation, reducing eosinophil recruitment and activity. This mechanism has been highly effective in diseases with an established type 2 inflammatory component, such as asthma, atopic dermatitis, and chronic rhinosinusitis.

In the context of COPD, dupilumab’s action on IL-4 and IL-13 could attenuate the eosinophilic inflammation seen in some patients, leading to reduced exacerbations, improved lung function, and better overall disease control. This is particularly relevant for patients with high eosinophil counts, who may not respond adequately to traditional COPD treatments.

Emerging Clinical Evidence

Several recent studies have explored the potential of dupilumab for COPD. Early clinical trials have demonstrated a reduction in exacerbation rates and improvements in lung function in COPD patients with eosinophilic inflammation treated with dupilumab. One phase II clinical trial (LIBERTY COPD) investigated the efficacy of dupixent for COPD patients with elevated eosinophil levels. Results showed a significant reduction in the rate of moderate-to-severe exacerbations compared to placebo, as well as improvements in forced expiratory volume in one second (FEV1), a key measure of lung function.

These promising outcomes suggest that dupilumab may be particularly beneficial for COPD patients with elevated blood eosinophils, who typically experience frequent exacerbations and are often less responsive to conventional therapies. Furthermore, the safety profile of dupilumab in COPD patients has been consistent with its use in other diseases, with no new safety concerns emerging from the trials.

Implications for Clinical Practice

If ongoing clinical trials continue to show favorable results, dupilumab could represent a major advancement in the treatment of COPD, particularly for patients with type 2 inflammation. Identifying patients with elevated eosinophil counts would be crucial in selecting candidates for dupilumab therapy, aligning with the growing trend of personalized medicine in respiratory diseases.

Dupilumab could complement existing COPD therapies, such as bronchodilators and ICS, offering an additional mechanism to control inflammation in patients who remain symptomatic despite standard treatment. The introduction of Dupixent for COPD would expand the therapeutic arsenal for this challenging disease and may lead to improved outcomes for a significant subset of patients.

Conclusion

Chronic obstructive pulmonary disease remains a significant public health challenge, with many patients experiencing poor disease control despite current therapeutic options. The discovery of a type 2 inflammatory subtype in COPD has opened the door to targeted biologic therapies, such as dupilumab. By inhibiting the IL-4 and IL-13 signaling pathways, Dupixent for COPD offers a promising new approach for managing patients with eosinophilic inflammation. Ongoing clinical trials will further elucidate its efficacy and safety in this population, potentially establishing dupilumab as a valuable addition to COPD treatment protocols.

Update February 8, 2025

A recent study titled “Clinical effectiveness and safety of dupilumab in patients with COPD disease: A 7 year population based cohort study” concluded that in patients with COPD, Dupixent was associated with a lower mortality rate, fewer ER visits and a reduced risk of acute exacerbations, respiratory symptoms and respiratory infections.

Update December 26, 2025

The Lancet published that add-on dupilumab, was found to reduce exacerbations in patients with COPD with type 2 inflammation and on triple therapy in the BOREAS phase 3 randomized placebo controlled study. These findings showed that dupilumab reduces type 2 inflammatory biomarkers in COPD.

Filed Under: biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page